This renewal application builds upon our recent studies indicating that aldehyde dehydrogenase (ALDH) enzymes can be critical metabolic switches that link chromatin remodeling with gene expression in vascular and inflammatory cells, and that the dysregulation of specific ALDH isoforms is linked in the pathogenesis of pulmonary arterial hypertension (PAH). We use pulmonary arterial (PA) endothelial cells (EC), smooth muscle cells (SMC) and macrophages (M) and genetically modified mice to pursue our novel observations. Our Preliminary Data reveal increased mRNA and protein levels of ALDH1A3 in PA SMC from patients with PAH versus controls, which is required for their heightened proliferation. The mechanism is related to elevated nuclear production of acetyl CoA, acetylation of histones at enhancer marks (H3K27ac) and expression of genes associated with cell cycle progression.
In Aim 1, we use RNA Seq and ChIP Seq to probe the mechanism by which elevated ALDH1A3 increases cell cycle genes as well as other metabolic enzymes, i.e., PKM2, DLD and IDH1 and we study the impact of those enzymes on chromatin remodeling and gene expression. We investigate whether elevated ALDH1A3 could be regulated by mechanisms that are dependent a well as independent of BMPR2. Further experiments test whether deleting Aldh1a3 in SMC of genetically modified mice is sufficient to attenuate proliferation of PA SMC and pulmonary hypertension (PH) associated with chronic hypoxia. In PA EC, we found that a different ALDH isoform ALDH3A1, is increased in response to laminar flow. In contrast, ALDH2 a mitochondrial enzyme is elevated under static or disturbed flow conditions. Both ALDH isoforms are expected to preserve PA EC function through multiple metabolic pathways that affect gene expression.
Aim 2 will determine whether ALDH3A1 protects PA EC under laminar flow and ALDH2 under static conditions by relating their metabolomic profile to chromatin accessibility and gene expression. Localization of these ALDH isoforms will be studied in control and PAH lungs using 3-D vibratome imaging. Aldh3a1 or Aldh2 will be deleted in EC from genetically modified mice to determine whether this causes more severe PH following chronic hypoxia or 5-lipoxygenase mediated inflammation.
In Aim 3 we focus on ALDH1A2, an ALDH isoform implicated in polarization of M associated with resolution of inflammation, similar to the reported effect of BMPR2 ligands. We will determine whether deleting Aldh1a2 or Bmpr2 in interstitial M recruited to the lung in association with PH producing conditions, causes more severe disease related to persistent perivascular inflammation. Proteomics will be applied to analyze the secretome of these Aldh1a2 or Bmpr2 deleted M to better define the nature of the inflammatory response. The impact of the M with Aldh1a2 or Bmpr2 deleted on EC apoptosis or endothelial mesenchymal transition will also be investigated. Our studies are timely in addressing the significance of ADLH isoforms in PAH as small molecule agonists and antagonists of ALDH enzymes are being developed and tested in the clinic.

Public Health Relevance

We link abnormal expression of members of the aldehyde dehydrogenase family of enzymes to changes in metabolism, chromatin and gene expression that adversely impact vascular and inflammatory cell function in pulmonary arterial hypertension. Our studies test the significance of our findings in human cells and tissues as well as in genetically modified mice.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL074186-14
Application #
9661151
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Xiao, Lei
Project Start
2004-04-01
Project End
2023-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
14
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Stanford University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Zamanian, Roham T; Hedlin, Haley; Greuenwald, Paul et al. (2018) Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 197:788-800
Miyagawa, Kazuya; Shi, Minyi; Chen, Pin-I et al. (2018) Smooth Muscle Contact Drives Endothelial Regeneration by BMPR2-Notch1 Mediated Metabolic and Epigenetic Changes. Circ Res :
Tojais, Nancy F; Cao, Aiqin; Lai, Ying-Ju et al. (2017) Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-? in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol 37:1559-1569
Bonnet, S├ębastien; Provencher, Steeve; Guignabert, Christophe et al. (2017) Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 195:583-595
Newman, John H; Rich, Stuart; Abman, Steven H et al. (2017) Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. Am J Respir Crit Care Med 195:1661-1670
Chen, Pin-I; Cao, Aiqin; Miyagawa, Kazuya et al. (2017) Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension. JCI Insight 2:e90427
Rabinovitch, Marlene (2016) NETs Activate Pulmonary Arterial Endothelial Cells. Arterioscler Thromb Vasc Biol 36:2035-7
Hopper, Rachel K; Moonen, Jan-Renier A J; Diebold, Isabel et al. (2016) In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug. Circulation 133:1783-94
Amsallem, Myriam; Kuznetsova, Tatiana; Hanneman, Kate et al. (2016) Right heart imaging in patients with heart failure: a tale of two ventricles. Curr Opin Cardiol 31:469-82
Vattulainen-Collanus, Sanna; Akinrinade, Oyediran; Li, Molong et al. (2016) Loss of PPAR? in endothelial cells leads to impaired angiogenesis. J Cell Sci 129:693-705

Showing the most recent 10 out of 39 publications